Vaderis Therapeutics raised a Series B to run a Phase 3 study of its AKT inhibitor engasertib in a rare blood disorder called hereditary hemorrhagic telangiectasia.
Vaderis Therapeutics’ bet that a type of treatment developed for cancers could work for a rare blood disorder is paying off.
The 13-person Swiss startup …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic…
BASEL, Switzerland and LINCOLNSHIRE, Ill., Aug. 11, 2026 /PRNewswire/ -- Vaderis Therapeutics, a clinical-stage biopharmaceutical…
Incyte plans to buy Star Therapeutics and its Phase 3 bleeding disorder candidate.
Incyte CEO Bill Meury acquires Vega Therapeutics for up to $2B, adding Phase 3 von Willebrand disease drug as Jakafi faces 2028…
Incyte to acquire Vega Therapeutics for $1.25 billion upfront, adding a rare bleeding disorder candidate with blockbuster…
Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in…
